vigabatrin has been researched along with Adenoma Sebaceum in 64 studies
Adenoma Sebaceum: Facial ANGIOFIBROMA in tuberous sclerosis
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients." | 9.12 | Vigabatrin - new data on indications and safety in paediatric epilepsy. ( Golec, W; Jóźwiak, S; Jurkiewicz, E; Sołowiej, E; Strzelecka, J, 2021) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 9.08 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "Vigabatrin (VGB) was found to be an effective anti-epileptic drug to reduce infantile spasms in about 50% of patients and it has been found most effective in infantile spasms due to tuberous sclerosis (TSC) in which up to 95% of infants had complete cessation of their spasms." | 8.81 | Vigabatrin for tuberous sclerosis complex. ( Bombardieri, R; Curatolo, P; Verdecchia, M, 2001) |
| "The purpose of this report is to review the efficacy and safety of vigabatrin in the treatment of infantile spasms in infants suffering from tuberous sclerosis complex." | 8.80 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| "We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period." | 8.12 | Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? ( Chen, L; Chen, Y; Hu, Y; Liao, J; Lin, S; Liu, G; Scheffer, IE; Su, Q; Wen, F; Yao, Y; Zhao, X, 2022) |
| "Vigabatrin therapy is commonly used in infants diagnosed with tuberous sclerosis complex, particularly in the setting of epilepsy." | 8.02 | Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis. ( Cardenas, AM; Craft, JF, 2021) |
| "Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known." | 7.88 | Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. ( Peters, JM; Sahin, M; van der Poest Clement, EA, 2018) |
| "Objective: To evaluate the effects and tolerability of vigabatrin (VGB) in children with tuberous sclerosis (TS) with infantile spasms or tonic seizures." | 7.83 | Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms. ( Hino-Fukuyo, N; Kiluchi, A; Kobayashi, T; Kure, S; Nakayama, T; Numata-Uematsu, Y; Sato, H; Suzuki-Muromoto,, S; Uematsu, M, 2016) |
| "This retrospective study reviewed the Hospital for Sick Children's experience with the short-term efficacy of vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex." | 7.81 | Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex. ( Boyd, J; Go, C; Jones, K; McCoy, B; Ochi, A; Puka, K; Snead, OC, 2015) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 7.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "Vigabatrin (VGB) has been shown to be particularly effective in the treatment of infantile spasms for those with tuberous sclerosis complex (TSC)." | 7.79 | Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. ( Bogner, M; Devinsky, O; Friedman, D; Parker-Menzer, K, 2013) |
| " Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined." | 7.79 | Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. ( Ko, TS; Lee, EH; Yum, MS, 2013) |
| "Vigabatrin (VGB) is one of the most effective anti-epileptic drugs for tonic spasms, those accompanied with tuberous sclerosis complex (TSC), but is not available in Japan." | 7.76 | [Effectiveness of vigabatrin in west syndrome associated with tuberous sclerosis]. ( Ando, N; Fujimoto, S; Hattori, A; Ishikawa, T; Ito, T; Kobayashi, S; Togari, H, 2010) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 7.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "To report the efficacy of vigabatrin in seizures control, as well as the electroencephalographic abnormalities in children with tuberous sclerosis and West syndrome." | 7.72 | [Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis]. ( da Silva, AR; Ohlweiler, L; Riesgo, R; Rotta, NT, 2003) |
| "Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis." | 7.70 | Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 7.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| " For each patient we recorded dates of infantile spasms onset, response to vigabatrin, relapse (if any), and quantified duration and dosage of vigabatrin after response." | 5.48 | High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. ( Bebin, EM; Goyal, M; Hussain, SA; Krueger, DA; Northrup, H; Peters, JM; Sahin, M; Schmid, E; Wu, JY, 2018) |
| "Early EEG findings help to identify TSC infants at risk of severe epilepsy and neurodevelopmental delay and those who may benefit from preventive treatment with vigabatrin." | 5.41 | Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes. ( Aronica, E; Benova, B; Curatolo, P; De Ridder, J; Domanska-Pakieła, D; Ferrier, CH; Feucht, M; Hertzberg, C; Jansen, AC; Jansen, FE; Jóźwiak, S; Kaczorowska-Frontczak, M; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Lemmens, K; Moavero, R; Nabbout, R; Riney, K; Samueli, S; Verhelle, B; Vervisch, J; Weschke, B; Wojdan, K, 2021) |
| "Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy." | 5.41 | Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. ( Aronica, E; Benova, B; Borkowska, J; Curatolo, P; de Ridder, J; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Hulshof, H; Jansen, AC; Jansen, F; Jóźwiak, S; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Moavero, R; Nabbout, R; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Weschke, B; Wojdan, K, 2021) |
| "We performed a prospective, nonrandomized clinical trial with 14 infants diagnosed with tuberous sclerosis complex in whom serial electroencephalographic recordings were performed and preventive treatment with vigabatrin initiated when active epileptic discharges were detected." | 5.30 | Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial. ( Borkowska, J; Chmielewski, D; Domańska-Pakieła, D; Głowacka, J; Jozwiak, S; Kaczorowska-Frontczak, M; Kotulska, K; Sadowski, K; Sijko, K; Słowińska, M; Łojszczyk, B, 2019) |
| "Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients." | 5.12 | Vigabatrin - new data on indications and safety in paediatric epilepsy. ( Golec, W; Jóźwiak, S; Jurkiewicz, E; Sołowiej, E; Strzelecka, J, 2021) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 5.08 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "Vigabatrin (VGB) was found to be an effective anti-epileptic drug to reduce infantile spasms in about 50% of patients and it has been found most effective in infantile spasms due to tuberous sclerosis (TSC) in which up to 95% of infants had complete cessation of their spasms." | 4.81 | Vigabatrin for tuberous sclerosis complex. ( Bombardieri, R; Curatolo, P; Verdecchia, M, 2001) |
| "The purpose of this report is to review the efficacy and safety of vigabatrin in the treatment of infantile spasms in infants suffering from tuberous sclerosis complex." | 4.80 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| "We present a comprehensive multi-omic analysis of the EPISTOP prospective clinical trial of early intervention with vigabatrin for pre-symptomatic epilepsy treatment in Tuberous Sclerosis Complex (TSC), in which 93 infants with TSC were followed from birth to age 2 years, seeking biomarkers of epilepsy development." | 4.31 | Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years. ( Anink, JJ; Aronica, E; Asara, JM; Blazejczyk, M; Borkowska, J; Curatolo, P; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Huschner, F; Iyer, A; Jansen, AC; Jansen, FE; Janson, S; Janssen, B; Jaworski, J; Jozwiak, S; Klonowska, K; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Lasseter, K; Lehmann, K; Mijnsbergen, C; Mills, JD; Moavero, R; Mühlebner, A; Nabbout, R; Petrák, B; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Tempes, A; Urbanska, M; van Scheppingen, J; Weschke, B; Wojdan, K; Zamecnik, J, 2023) |
| "We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period." | 4.12 | Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? ( Chen, L; Chen, Y; Hu, Y; Liao, J; Lin, S; Liu, G; Scheffer, IE; Su, Q; Wen, F; Yao, Y; Zhao, X, 2022) |
| " Prophylactic intervention with sirolimus and vigabatrin may reduce the incidence of epilepsy." | 4.12 | Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex. ( Ding, Y; Wang, J; Wang, X; Wang, Y; Yu, L; Zhou, S; Zhou, Y, 2022) |
| "Vigabatrin therapy is commonly used in infants diagnosed with tuberous sclerosis complex, particularly in the setting of epilepsy." | 4.02 | Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis. ( Cardenas, AM; Craft, JF, 2021) |
| "Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known." | 3.88 | Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. ( Peters, JM; Sahin, M; van der Poest Clement, EA, 2018) |
| "Objective: To evaluate the effects and tolerability of vigabatrin (VGB) in children with tuberous sclerosis (TS) with infantile spasms or tonic seizures." | 3.83 | Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms. ( Hino-Fukuyo, N; Kiluchi, A; Kobayashi, T; Kure, S; Nakayama, T; Numata-Uematsu, Y; Sato, H; Suzuki-Muromoto,, S; Uematsu, M, 2016) |
| "This retrospective study reviewed the Hospital for Sick Children's experience with the short-term efficacy of vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex." | 3.81 | Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex. ( Boyd, J; Go, C; Jones, K; McCoy, B; Ochi, A; Puka, K; Snead, OC, 2015) |
| " Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined." | 3.79 | Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. ( Ko, TS; Lee, EH; Yum, MS, 2013) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 3.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "Vigabatrin (VGB) has been shown to be particularly effective in the treatment of infantile spasms for those with tuberous sclerosis complex (TSC)." | 3.79 | Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. ( Bogner, M; Devinsky, O; Friedman, D; Parker-Menzer, K, 2013) |
| " We retrospectively evaluated the long-term outcome of 44 infants presenting with seizures in the first 12 months who received vigabatrin, and were followed up for at least 3." | 3.77 | Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. ( Bombardieri, R; Curatolo, P; Cusmai, R; Moavero, R; Vigevano, F, 2011) |
| "Vigabatrin (VGB) is one of the most effective anti-epileptic drugs for tonic spasms, those accompanied with tuberous sclerosis complex (TSC), but is not available in Japan." | 3.76 | [Effectiveness of vigabatrin in west syndrome associated with tuberous sclerosis]. ( Ando, N; Fujimoto, S; Hattori, A; Ishikawa, T; Ito, T; Kobayashi, S; Togari, H, 2010) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 3.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| " The child was treated with vigabatrin at age 6 months after an abnormal electroencephalogram but before onset of seizures." | 3.73 | Autistic regression associated with seizure onset in an infant with tuberous sclerosis. ( Bolton, PF; Clarke, A; Humphrey, A; Neville, BG, 2006) |
| "To report the efficacy of vigabatrin in seizures control, as well as the electroencephalographic abnormalities in children with tuberous sclerosis and West syndrome." | 3.72 | [Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis]. ( da Silva, AR; Ohlweiler, L; Riesgo, R; Rotta, NT, 2003) |
| "Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis." | 3.70 | Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 3.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "To study the pharmacokinetics of vigabatrin in a patient affected with tuberous sclerosis who developed major agitation and aggression, while receiving vigabatrin orally (1." | 3.69 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| "Vigabatrin is the treatment of choice when the underlying cause is tuberous sclerosis complex (TSC)." | 2.53 | Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy. ( Appleton, R; Iyer, A, 2016) |
| "When infantile spasms are accompanied by hypsarrhythmia on electroencephalogram, the condition is labeled West syndrome." | 2.47 | Vigabatrin for infantile spasms. ( Belliveau, P; Pesaturo, KA; Spooner, LM, 2011) |
| "Vigabatrin has been shown to be particularly effective in treating infantile spasms in the setting of tuberous sclerosis complex." | 2.42 | Managing epilepsy in tuberous sclerosis complex. ( Thiele, EA, 2004) |
| "Vigabatrin is a preferred drug in patients younger than two years old for both focal (61." | 1.62 | Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. ( Fladrowski, C; Jóźwiak, S; Kotulska, K; Roberds, SL; Szymańska, S; Słowińska, M, 2021) |
| "An epilepsy mouse model for Tuberous Sclerosis Complex (TSC) was developed and validated to investigate the mechanisms underlying epileptogenesis." | 1.51 | Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model. ( Elgersma, Y; Koene, LMC; Kooijman, NHRM; Proietti Onori, M; Schreiber, J; van Grondelle, SE; van Oort, A; Wallaard, I, 2019) |
| " For each patient we recorded dates of infantile spasms onset, response to vigabatrin, relapse (if any), and quantified duration and dosage of vigabatrin after response." | 1.48 | High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. ( Bebin, EM; Goyal, M; Hussain, SA; Krueger, DA; Northrup, H; Peters, JM; Sahin, M; Schmid, E; Wu, JY, 2018) |
| "We describe two infants with tuberous sclerosis complex whose surveillance EEG showed focal seizures that were not previously recognized by caregivers." | 1.46 | The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex. ( Jan, S; McCoy, B; Whitney, R; Zak, M, 2017) |
| "OCT and complete dosing data was available for 19 patients." | 1.43 | Optical coherence tomography to monitor vigabatrin toxicity in children. ( Alexander, J; Bazemore, M; Berl, MM; de Beaufort, H; Elling, N; Geddie, B; Hutcheson, K; Jaafar, MS; Karwoski, B; Madigan, W; McClintock, W; Miller, M; Origlieri, C; Taylormoore, J, 2016) |
| "Valproic acid was prescribed most frequently as first and second treatment, followed by vigabatrin." | 1.42 | Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. ( Bindels-de Heus, K; de Wit, MC; Moll, HA; Overwater, IE; Rietman, AB; Ten Hoopen, LW; Vergouwe, Y, 2015) |
| "Introduccion." | 1.39 | [Characterisation of the paediatric population of Costa Rica with tuberous sclerosis and a description of the behaviour of the associated epilepsy]. ( Benavides-Lara, A; Hernández, L; Ulate-Campos, A, 2013) |
| "Epilepsy is very common in tuberous sclerosis and occurs in 75-92% of affected individuals during their life-time." | 1.38 | [The course and treatment of epilepsy in children with tuberose sclerosis]. ( Belousova, ED; Dorofeeva, MIu, 2012) |
| "Early control of seizures has a crucial role in preventing subsequent epileptic encephalopathy, and in reducing the cognitive/behavioural consequences of seizures, but does not guarantee for a normal mental outcome in children with TSC." | 1.36 | Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. ( Bombardieri, R; Cerminara, C; Curatolo, P; Moavero, R; Pinci, M, 2010) |
| "Vigabatrin has proved to be effective against infantile spasms due to TSC." | 1.35 | Management of epilepsy in tuberous sclerosis complex. ( Bombardieri, R; Cerminara, C; Curatolo, P; D'Argenzio, L, 2008) |
| "Tuberous sclerosis is a multisystem autosomal-dominant disease characterized by hamartomatous growths in the brain, skin, kidneys, eyes, and heart, but it may affect almost any organ." | 1.35 | Unilateral eyelid angiofibroma with complete blepharoptosis as the presenting sign of tuberous sclerosis. ( Lopez, JP; Miller, P; Ossandón, D; Sánchez, L; Winter, A, 2009) |
| "The diagnostic criteria for tuberous sclerosis complex (TSC) have recently been revised." | 1.32 | Spectrum of epilepsy in tuberous sclerosis. ( Anisya-Vasanth, AV; Jayakumar, PN; Nagaraja, D; Satishchandra, P; Swamy, HS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (10.94) | 18.2507 |
| 2000's | 17 (26.56) | 29.6817 |
| 2010's | 26 (40.63) | 24.3611 |
| 2020's | 14 (21.88) | 2.80 |
| Authors | Studies |
|---|---|
| Golec, W | 1 |
| Sołowiej, E | 1 |
| Strzelecka, J | 1 |
| Jurkiewicz, E | 1 |
| Jóźwiak, S | 8 |
| Lin, S | 1 |
| Liao, J | 1 |
| Zhao, X | 1 |
| Hu, Y | 1 |
| Chen, L | 1 |
| Chen, Y | 1 |
| Liu, G | 1 |
| Yao, Y | 1 |
| Su, Q | 1 |
| Scheffer, IE | 1 |
| Wen, F | 1 |
| Wang, X | 1 |
| Ding, Y | 1 |
| Zhou, Y | 1 |
| Yu, L | 1 |
| Zhou, S | 1 |
| Wang, Y | 1 |
| Wang, J | 1 |
| de Saint Martin, A | 1 |
| Napuri, S | 1 |
| Nguyen, S | 1 |
| Huschner, F | 1 |
| Głowacka-Walas, J | 2 |
| Mills, JD | 1 |
| Klonowska, K | 2 |
| Lasseter, K | 1 |
| Asara, JM | 1 |
| Moavero, R | 7 |
| Hertzberg, C | 4 |
| Weschke, B | 4 |
| Riney, K | 4 |
| Feucht, M | 4 |
| Scholl, T | 2 |
| Krsek, P | 4 |
| Nabbout, R | 5 |
| Jansen, AC | 4 |
| Petrák, B | 1 |
| van Scheppingen, J | 1 |
| Zamecnik, J | 1 |
| Iyer, A | 2 |
| Anink, JJ | 1 |
| Mühlebner, A | 1 |
| Mijnsbergen, C | 1 |
| Lagae, L | 4 |
| Curatolo, P | 12 |
| Borkowska, J | 4 |
| Sadowski, K | 4 |
| Domańska-Pakieła, D | 5 |
| Blazejczyk, M | 1 |
| Jansen, FE | 3 |
| Janson, S | 1 |
| Urbanska, M | 1 |
| Tempes, A | 1 |
| Janssen, B | 1 |
| Sijko, K | 3 |
| Wojdan, K | 4 |
| Kotulska, K | 7 |
| Lehmann, K | 1 |
| Aronica, E | 4 |
| Jaworski, J | 1 |
| Kwiatkowski, DJ | 5 |
| Słowińska, M | 2 |
| Łojszczyk, B | 1 |
| Chmielewski, D | 1 |
| Kaczorowska-Frontczak, M | 2 |
| Głowacka, J | 1 |
| Choudhury, P | 1 |
| Spaull, R | 1 |
| Amin, S | 1 |
| Mallick, AA | 1 |
| Patel, JS | 1 |
| O'Callaghan, F | 1 |
| Lux, AL | 2 |
| Grinspan, ZM | 1 |
| Mytinger, JR | 1 |
| Baumer, FM | 1 |
| Ciliberto, MA | 1 |
| Cohen, BH | 1 |
| Dlugos, DJ | 1 |
| Harini, C | 1 |
| Hussain, SA | 2 |
| Joshi, SM | 1 |
| Keator, CG | 1 |
| Knupp, KG | 1 |
| McGoldrick, PE | 1 |
| Nickels, KC | 1 |
| Park, JT | 1 |
| Pasupuleti, A | 1 |
| Patel, AD | 1 |
| Pomeroy, SL | 1 |
| Shahid, AM | 1 |
| Shellhaas, RA | 1 |
| Shrey, DW | 1 |
| Singh, RK | 1 |
| Wolf, SM | 1 |
| Yozawitz, EG | 1 |
| Yuskaitis, CJ | 1 |
| Waugh, JL | 1 |
| Pearl, PL | 1 |
| Uematsu, M | 2 |
| Numata-Uematsu, Y | 2 |
| Aihara, Y | 1 |
| Kobayashi, T | 2 |
| Fujikawa, M | 1 |
| Togashi, N | 1 |
| Shiihara, T | 1 |
| Ohashi, K | 1 |
| Hattori, A | 2 |
| Saitoh, S | 1 |
| Kure, S | 2 |
| Benvenuto, A | 1 |
| Emberti Gialloreti, L | 1 |
| Van Schooneveld, MM | 1 |
| Samueli, S | 2 |
| Maulisovà, A | 1 |
| Jansen, F | 1 |
| Hulshof, H | 1 |
| Benova, B | 2 |
| de Ridder, J | 2 |
| Szymańska, S | 1 |
| Roberds, SL | 1 |
| Fladrowski, C | 1 |
| Craft, JF | 1 |
| Cardenas, AM | 1 |
| Verhelle, B | 1 |
| Vervisch, J | 1 |
| Lemmens, K | 1 |
| Ferrier, CH | 1 |
| Kuchenbuch, M | 1 |
| Chiron, C | 5 |
| Whitney, R | 1 |
| Jan, S | 1 |
| Zak, M | 1 |
| McCoy, B | 2 |
| van der Poest Clement, EA | 1 |
| Sahin, M | 4 |
| Peters, JM | 3 |
| Suzuki-Muromoto,, S | 1 |
| Sato, H | 1 |
| Nakayama, T | 1 |
| Kiluchi, A | 1 |
| Hino-Fukuyo, N | 1 |
| Schmid, E | 1 |
| Goyal, M | 1 |
| Bebin, EM | 1 |
| Northrup, H | 1 |
| Krueger, DA | 2 |
| Wu, JY | 1 |
| Salussolia, CL | 1 |
| Koene, LMC | 1 |
| van Grondelle, SE | 1 |
| Proietti Onori, M | 1 |
| Wallaard, I | 1 |
| Kooijman, NHRM | 1 |
| van Oort, A | 1 |
| Schreiber, J | 1 |
| Elgersma, Y | 1 |
| Zhang, B | 1 |
| McDaniel, SS | 1 |
| Rensing, NR | 1 |
| Wong, M | 1 |
| Ulate-Campos, A | 1 |
| Benavides-Lara, A | 1 |
| Hernández, L | 1 |
| Riikonen, R | 1 |
| Rener-Primec, Z | 1 |
| Carmant, L | 1 |
| Dorofeeva, M | 1 |
| Hollody, K | 1 |
| Szabo, I | 1 |
| Krajnc, BS | 1 |
| Wohlrab, G | 1 |
| Sorri, I | 1 |
| Davis, PE | 1 |
| Overwater, IE | 1 |
| Bindels-de Heus, K | 1 |
| Rietman, AB | 1 |
| Ten Hoopen, LW | 1 |
| Vergouwe, Y | 1 |
| Moll, HA | 1 |
| de Wit, MC | 1 |
| Jones, K | 1 |
| Go, C | 1 |
| Boyd, J | 1 |
| Ochi, A | 1 |
| Puka, K | 1 |
| Snead, OC | 1 |
| Origlieri, C | 1 |
| Geddie, B | 1 |
| Karwoski, B | 1 |
| Berl, MM | 1 |
| Elling, N | 1 |
| McClintock, W | 1 |
| Alexander, J | 1 |
| Bazemore, M | 1 |
| de Beaufort, H | 1 |
| Hutcheson, K | 1 |
| Miller, M | 1 |
| Taylormoore, J | 1 |
| Jaafar, MS | 1 |
| Madigan, W | 1 |
| Appleton, R | 1 |
| Muzykewicz, DA | 1 |
| Costello, DJ | 1 |
| Halpern, EF | 1 |
| Thiele, EA | 4 |
| Bombardieri, R | 5 |
| Pinci, M | 1 |
| Cerminara, C | 3 |
| Lopez, JP | 1 |
| Ossandón, D | 1 |
| Miller, P | 1 |
| Sánchez, L | 1 |
| Winter, A | 1 |
| Rhim, Jw | 1 |
| Yoo, C | 1 |
| Kim, SH | 1 |
| Nandhagopal, R | 1 |
| Thapa, M | 1 |
| Khanna, PC | 1 |
| Ando, N | 1 |
| Fujimoto, S | 1 |
| Ishikawa, T | 1 |
| Kobayashi, S | 1 |
| Ito, T | 1 |
| Togari, H | 1 |
| Pesaturo, KA | 1 |
| Spooner, LM | 1 |
| Belliveau, P | 1 |
| Cusmai, R | 1 |
| Vigevano, F | 1 |
| Yum, MS | 1 |
| Lee, EH | 1 |
| Ko, TS | 1 |
| Hsieh, DT | 1 |
| Dorofeeva, MIu | 1 |
| Belousova, ED | 1 |
| Friedman, D | 1 |
| Bogner, M | 1 |
| Parker-Menzer, K | 1 |
| Devinsky, O | 1 |
| Edwards, SW | 1 |
| Osborne, JP | 2 |
| Hancock, E | 2 |
| Johnson, AL | 1 |
| Verity, CM | 1 |
| Kennedy, CR | 1 |
| O'Callaghan, FJ | 1 |
| Newton, RW | 1 |
| Rotta, NT | 1 |
| da Silva, AR | 1 |
| Ohlweiler, L | 1 |
| Riesgo, R | 1 |
| Anisya-Vasanth, AV | 1 |
| Satishchandra, P | 1 |
| Nagaraja, D | 1 |
| Swamy, HS | 1 |
| Jayakumar, PN | 1 |
| Humphrey, A | 1 |
| Neville, BG | 1 |
| Clarke, A | 1 |
| Bolton, PF | 1 |
| Kaczorowska, M | 1 |
| D'Argenzio, L | 1 |
| Camposano, SE | 1 |
| Major, P | 1 |
| Halpern, E | 1 |
| Aicardi, J | 1 |
| Mumford, JP | 2 |
| Dumas, C | 3 |
| Wood, S | 1 |
| López-Valdés, E | 1 |
| Hernández-Laín, A | 1 |
| Simón, R | 1 |
| Porta, J | 1 |
| Mateos, F | 1 |
| Jambaqué, I | 2 |
| Mumford, J | 2 |
| Dulac, O | 3 |
| Jacqz-Aigrain, E | 1 |
| Guillonneau, M | 1 |
| Rey, E | 1 |
| Macher, MA | 1 |
| Montes, C | 1 |
| Loirat, C | 1 |
| Riikonen, RS | 1 |
| Prasad, AN | 1 |
| Penney, S | 1 |
| Buckley, DJ | 1 |
| Verdecchia, M | 1 |
| Luna, D | 1 |
| Palacios, L | 1 |
| Mondragon, S | 1 |
| Beaumont, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial[NCT04302116] | 250 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for vigabatrin and Adenoma Sebaceum
| Article | Year |
|---|---|
Vigabatrin - new data on indications and safety in paediatric epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Spasms, Infantile; Tuberous Sclerosis; Vigabatrin | 2021 |
Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis.
Topics: Anticonvulsants; Child; Early Diagnosis; Epilepsy; Humans; Infant; Infant, Newborn; Seizures; Tubero | 2022 |
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.
Topics: Anticonvulsants; Cannabidiol; Humans; MTOR Inhibitors; Seizures; Tuberous Sclerosis; Vigabatrin | 2021 |
Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Topics: Everolimus; Gene Expression Regulation; Genotype; Humans; Mental Disorders; Mutation; Neurogenesis; | 2019 |
Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Topics: Animals; Autism Spectrum Disorder; Brain; Epilepsy; GABA Agents; Humans; Neurons; TOR Serine-Threoni | 2015 |
Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyridoxine; S | 2016 |
Vigabatrin for infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Clinical Trials as Topic; Electroenc | 2011 |
Managing epilepsy in tuberous sclerosis complex.
Topics: Anticonvulsants; Child; Cognition Disorders; Diet Therapy; Electroencephalography; Epilepsy; Humans; | 2004 |
Current management for epilepsy in tuberous sclerosis complex.
Topics: Animals; Anticonvulsants; Brain Injuries; Cognition Disorders; Epilepsy; Humans; Neurosurgery; Tuber | 2006 |
Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Infant; Spasms, Infantile; Tuberous Sclerosis; Vig | 1999 |
Steroids or vigabatrin in the treatment of infantile spasms?
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Infant, Newborn; Spasms, Infantile; Tu | 2000 |
Vigabatrin for tuberous sclerosis complex.
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; Humans; Infant; Tuberous Sclerosis; Vi | 2001 |
6 trials available for vigabatrin and Adenoma Sebaceum
| Article | Year |
|---|---|
Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial.
Topics: Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Follow-Up | 2019 |
Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?
Topics: Anticonvulsants; Autism Spectrum Disorder; Child, Preschool; Developmental Disabilities; Epilepsy; F | 2020 |
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Electroencephalography; Epilepsy; Female; Humans; Infant; | 2021 |
Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes.
Topics: Anticonvulsants; Developmental Disabilities; Early Diagnosis; Electroencephalography; Epilepsy; Fema | 2021 |
Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups.
Topics: Age of Onset; Anticonvulsants; Child, Preschool; Dose-Response Relationship, Drug; Drug Administrati | 1996 |
Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.
Topics: Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Hydrocortisone; Infant; Infant, Newborn; M | 1997 |
46 other studies available for vigabatrin and Adenoma Sebaceum
| Article | Year |
|---|---|
Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures?
Topics: Anticonvulsants; Child; Epilepsies, Partial; Humans; Infant; Retrospective Studies; Seizures; Treatm | 2022 |
Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex.
Topics: Child; Epilepsy; Female; Humans; Male; Pregnancy; Prenatal Diagnosis; Prognosis; Prospective Studies | 2022 |
Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years.
Topics: Child, Preschool; Clinical Trials as Topic; Epilepsy; Humans; Infant; Infant, Newborn; Multiomics; P | 2023 |
Prophylactic Antiepileptic Treatment in Tuberous Sclerosis.
Topics: Anticonvulsants; Humans; Prospective Studies; Spasms, Infantile; Tuberous Sclerosis; Vigabatrin | 2020 |
Crisis Standard of Care: Management of Infantile Spasms during COVID-19.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Betacoronavirus; Coronavirus Infections; COVID-19; Del | 2020 |
Behavioral problems and family distress in tuberous sclerosis complex.
Topics: Adolescent; Anticonvulsants; Checklist; Child; Child, Preschool; Family Relations; Female; Humans; M | 2020 |
Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Health Care Surveys; Hum | 2021 |
Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis.
Topics: Humans; Infant; Magnetic Resonance Imaging; Male; Tuberous Sclerosis; Vigabatrin | 2021 |
The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex.
Topics: Anticonvulsants; Brain; Electroencephalography; Female; Humans; Infant; Prospective Studies; Seizure | 2017 |
Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex.
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Hu | 2018 |
Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Male; Spasms, Infantil | 2016 |
High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Prospective Studies | 2018 |
Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
Topics: Animals; Anticonvulsants; Brain; Diet, Ketogenic; Epilepsy; Female; Mechanistic Target of Rapamycin | 2019 |
Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Topics: Animals; Anticonvulsants; Astrocytes; Brain; Cell Proliferation; Cells, Cultured; Disease Models, An | 2013 |
[Characterisation of the paediatric population of Costa Rica with tuberous sclerosis and a description of the behaviour of the associated epilepsy].
Topics: Anticonvulsants; Autistic Disorder; Brain Diseases; Brain Neoplasms; Child, Preschool; Comorbidity; | 2013 |
Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Female; Humans; Infant; | 2015 |
Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diet, Ketogenic; Epilepsies, Partial; Epilepsy | 2015 |
Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Female; Follow-Up Studies | 2015 |
Optical coherence tomography to monitor vigabatrin toxicity in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroretinography; Female; Humans; Infant; M | 2016 |
Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anticonvulsants; Child; Child, Preschool; DNA Mutati | 2009 |
Early control of seizures improves long-term outcome in children with tuberous sclerosis complex.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroencephalography; F | 2010 |
Unilateral eyelid angiofibroma with complete blepharoptosis as the presenting sign of tuberous sclerosis.
Topics: Angiofibroma; Blepharoptosis; Eyelid Neoplasms; GABA Agents; Gestational Age; Humans; Infant, Newbor | 2009 |
Tuberous sclerosis with homonymous hemianopsia.
Topics: Anticonvulsants; Child; Epilepsy; Female; Hemianopsia; Humans; Magnetic Resonance Imaging; Tuberous | 2009 |
Can we change the course of epilepsy in tuberous sclerosis complex?
Topics: Epilepsy; Humans; Tuberous Sclerosis; Vigabatrin | 2010 |
Coexistence of cerebral tubers with neurocysticercosis.
Topics: Anticonvulsants; Brain Diseases; Child; Humans; Incidental Findings; Male; Neurocysticercosis; Seizu | 2010 |
Vigabatrin-associated diffusion MRI abnormalities in tuberous sclerosis.
Topics: Brain; Brain Diseases; Diffusion Magnetic Resonance Imaging; Enzyme Inhibitors; Humans; Infant; Male | 2010 |
[Effectiveness of vigabatrin in west syndrome associated with tuberous sclerosis].
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant; Male; Spasms, Infantile; Tuberous S | 2010 |
Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Developmental Disabilitie | 2011 |
Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures.
Topics: Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Intellectual Disa | 2013 |
Vigabatrin-related magnetic resonance imaging abnormalities in an infant with tuberous sclerosis complex and infantile spasms.
Topics: Enzyme Inhibitors; Humans; Infant; Magnetic Resonance Imaging; Spasms, Infantile; Tuberous Sclerosis | 2013 |
[The course and treatment of epilepsy in children with tuberose sclerosis].
Topics: Anticonvulsants; Child; Diet, Ketogenic; Epilepsy; Humans; Tuberous Sclerosis; Vigabatrin | 2012 |
Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex.
Topics: Anticonvulsants; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Seizures; Treatmen | 2013 |
Randomized trial of vigabatrin in patients with infantile spasms.
Topics: Child; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Infant; Randomize | 2002 |
[Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis].
Topics: Age of Onset; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Follow-Up St | 2003 |
Spectrum of epilepsy in tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; H | 2004 |
Autistic regression associated with seizure onset in an infant with tuberous sclerosis.
Topics: Anticonvulsants; Autistic Disorder; Developmental Disabilities; Epilepsy; Humans; Infant; Male; Regr | 2006 |
Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Humans; Infant; Prospective Studies; Spasms, Infa | 2007 |
Management of epilepsy in tuberous sclerosis complex.
Topics: Anticonvulsants; Child; Drug Resistance; Epilepsy; Gene Expression; Humans; Infant; Prognosis; Prote | 2008 |
Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Topics: Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroretinography; Epilepsies, Part | 2008 |
Vigabatrin for refractory partial seizures in children with tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; gamma-Aminobutyric Acid; Humans; Infant; Retro | 1994 |
[Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients].
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Ac | 1996 |
Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.
Topics: Adult; Anticonvulsants; Enzyme Inhibitors; gamma-Aminobutyric Acid; Humans; Kidney Failure, Chronic; | 1997 |
Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.
Topics: Anticonvulsants; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Drug Therapy, Com | 2000 |
The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 2001 |
Visual field constriction on vigabatrin.
Topics: Adult; Anticonvulsants; Epilepsy; Europe; Humans; Infant; Spasm; Treatment Outcome; Tuberous Scleros | 2000 |
Vigabatrin in infantile spasms.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Drug Evaluation; Humans; Infan | 1990 |